European Journal of Cancer
Volume 43, Issue 5 , Pages 852-858 , March 2007

International society of geriatric oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients

  • Jean-Jacques Body

      Affiliations

    • Université Libre de Bruxelles, Institut Jules Bordet and CHU Brugmann, Brussels, Belgium
    • Corresponding Author InformationCorresponding author: Tel.: +32 2 541 3303; fax: +32 2 541 3311.
    • ,
  • Rob Coleman

      Affiliations

    • Weston Park Hospital, Sheffield, UK
    • ,
  • Philippe Clezardin

      Affiliations

    • INSERMU.664, Lyon, France
    • ,
  • Carla Ripamonti

      Affiliations

    • Rehabilitation and Palliative Care Unit, National Cancer Institute of Milan, Italy
    • ,
  • Rene Rizzoli

      Affiliations

    • University Hospital, Geneva, Switzerland
    • ,
  • Matti Aapro

      Affiliations

    • Clinique de Genolier, Geneva, Switzerland

Received 18 September 2006 ,Revised 6 December 2006 ,Accepted 8 December 2006.

References 

  1. Goldschmidt H, Lannert H, Bommer J, Ho AD. Multiple myeloma and renal failure. Nephrol Dial Transplant. 2000;15:301–304
  2. Patterson WP, Reams GP. Renal toxicities of chemotherapy. Semin Oncol. 1992;19:521–858
  3. Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20:3719–3736
  4. Body JJ. Hypercalcemia of malignancy. Semin Nephrol. 2004;24:48–54
  5. Aredia® (pamidronate). SmPC. Novartis Pharmaceuticals UK. 4 January 2005.
  6. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol. 1998;16:2038–2044
  7. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol. 1999;17:846–854
  8. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996;334:488–493
  9. Tralongo P, Repetto L, Di Mari A, et al. Safety of long-term administration of bisphosphonates in elderly cancer patients. Oncology. 2004;67:112–116
  10. Mazj S, Lichtman SM. Renal dysfunction associated with bisphosphonate use: retrospective analysis of 293 patients with respect to age and other clinical characteristics. J Clin Oncol. 2004;22(Suppl. 14S):[Abstract 8039]
  11. Kloth DD, McDermott RS, Rogatko A, Langer CJ. Impact of zoledronic acid (Zol) on renal function in patients (pts) with cancer: is constant monitoring necessary. Proc Am Soc Clin Oncol. 2003;22:755;[Abstract 3036]
  12. Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 2003;64:281–289
  13. Stein SH, Davidson R, Tweed A, et al. Renal dysfunction with IV bisphosphonates in patients with metastatic breast cancer. Proc Am Soc Clin Oncol. 2003;22:745;[Abstract 2997]
  14. Johnson KB, Gable P, Kaime EM, Luiken G, Castillos T, Hu J. Significant deterioration in renal function with the new bisphosphonate, zoledronic acid. Proc Am Soc Clin Oncol. 2003;22:738;[Abstract 2968]
  15. Zometa® (zoledronic acid). Summary of product characteristics. Novartis Pharma. April 2005.
  16. Rosen LS, Gordon DH, Dugan W, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004;100:36–43
  17. Body JJ. Bisphosphonates for malignancy-related bone disease: current status, future developments. Support Care Cancer. 2006;14(5):408–418
  18. Body JJ. Safety and tolerability of bisphosphonates in the elderly: objective data. Presented at the 6th Meeting of ISGO/SIOG, Geneva; 2005.
  19. Paterson AHG, Powles TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 1993;11:59–65
  20. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet. 1992;340:1049–1052
  21. McCloskey EV, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol. 1998;100:317–325
  22. McCloskey EV, Dunn JA, Kanis JA, MacLennan ICM, Drayson MT. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol. 2001;113:1035–1043
  23. Jagdev SP, Purohit P, Heatley S, Herling C, Coleman RE. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol. 2001;12:1433–1438
  24. Atula S, Powles T, Paterson A, et al. Extended safety profile of oral clodronate after long-term use in primary breast cancer patients. Drug Safety. 2003;26:661–671
  25. Robertson AG, Reed NS, Ralston SH. Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol. 1995;13:2427–2430
  26. Bondronat® 50 mg film-coated tablets. Summary of product characteristics. Roche. June 2005.
  27. Melding PS. Is there such a thing as geriatric pain?. Pain. 1991;46:119–121
  28. Helme RD, Gibson SJ. Pain in older people. In:  Crombie IK, et al. editor. Epidemiology of pain. International Association for the Study of Pain Press; 1999;
  29. Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol. 1996;14:2552–2559
  30. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003;21:4277–4284
  31. Fulfaro F, Arcara C, Badalamenti G, et al. The use of zoledronic acid in the treatment of painful bone metastases from prostate cancer. Am Soc Clin Oncol. 2003;[Abstract 1721]
  32. Kretzschmar A, Wiegel T, Al-Batran SE, et al. Zoledronic acid (Z) as palliative treatment in cancer patients with bone metastases: interim results of a prospective, open-label trial. J Clin Oncol. 2004;22:760;[Abstract 8140]
  33. Vogel CL, Yanagihara RH, Wood AJ, et al. Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist. 2004;9:687–695
  34. Wardley A, Davidson N, Barrett-Lee P, et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer. 2005;92:1869–1876
  35. Vinholes J, Guo CY, Purohit OP, et al. Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer. 1996;73:1089–1095
  36. Lipton A, Demers L, Curley E, et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer. 1998;34:2021–2026
  37. Vinholes JJ, Purohit OP, Abbey ME, et al. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol. 1997;8:1243–1250
  38. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005;97:59–69
  39. Brown JE, Thomson CS, Ellis SP, et al. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer. 2003;89:2031–2037
  40. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005;23:4925–4935
  41. Body J, Lichinister M, Tjulandin S, Budde M, Bergström B. Effect of oral ibandronate versus intravenous (i.v.) zoledronic acid on markers of bone resorption in patients with breast cancer and bone metastases: results from a comparative phase III trial. ASCO Meeting Abstracts, June 1; 2005. p. 534.
  42. Body JJ, Lichinitser MR, Tjulandin SA, Coleman RE, Bergström B. Safety of oral ibandronate and intravenous zoledronic acid in breast cancer patients with metastatic bone disease. Breast Cancer Res Treat. 2005;94:S260;[Abstract 6035]
  43. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21:4042–4057
  44. Lipton A. Toward new horizons: the future of bisphosphonate therapy. Oncologist. 2004;9(Suppl. 4):38–47
  45. Walsh G. Hypodermoclysis: an alternate method for rehydration in long-term care. J Infus Nurs. 2005;28:123–129
  46. Woo S-B, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753–761
  47. Migliorati C, Casiglia J, Epstein J, et al. Managing the care of patients with bisphosphonate-associated osteonecrosis. JADA. 2005;136:1658–1668
  48. Ruggiero S, Gralow J, Marx RE, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Practice. 2006;2:7–14
  49. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone. An emerging complication of supportive cancer therapy. Cancer. 2005;104:83–93
  50. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the Jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23:8580–8587

PII: S0959-8049(06)01069-0

doi: 10.1016/j.ejca.2006.12.006

European Journal of Cancer
Volume 43, Issue 5 , Pages 852-858 , March 2007

Article Tools

* Image Usage & Resolution